Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 6/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4203085 | 0.85 | TGM2 (0.54) | BCHEACHEAPPTGM2SIRT2 | |
| SCHEMBL4365817 | 0.84 | APP (0.63) | BCHEACHEAPPTGM2SIRT2 | |
| SCHEMBL4376555 | 0.84 | BCHE (0.54) | BCHEACHEAPPTGM2SIRT2 | |
| SCHEMBL4207014 | 0.83 | APP (0.64) | BCHEACHEAPP | |
| SCHEMBL4365126 | 0.83 | APP (0.64) | BCHEACHEAPP | |
| SCHEMBL4208306 | 0.83 | APP (0.64) | BCHEACHEAPP | |
| SCHEMBL4204714 | 0.82 | APP (0.64) | BCHEACHEAPP | |
| SCHEMBL4375008 | 0.81 | TGM2 (0.53) | TGM2HTTALDH1A1KEAP1NFE2L2 | |
| SCHEMBL4371553 | 0.79 | APP (0.63) | BCHEACHEAPP | |
| SCHEMBL793834 | 0.79 | ALDH1A1 (0.47) | TGM2HTTALDH1A1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-7589219-B2 | 2,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2009-09-15 | — | — | US | disclosed |
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2005-11-24 | — | — | US | disclosed |
| EP-1497257-A1 | 2,5-BIS-DIAMINE-[1,4] BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE, A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | Alma Mater Studiorum -Universita' di Bologna (IT) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087035-A1 | 2,5-BIS-DIAMINE-'1,4! BENZOQUINONE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE A PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREFOR | ALMA MATER STUDIORUM-UNIVERSITA' DI BOLOGNA (IT) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261345-A1 | 2,5-Bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor | PSEN2, BACE2, WEE2 | BCHE 77/4885ACHE 169/4885APP 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.